NeoGenomics, Inc. revised earnings guidance for the fiscal year 2023. For the year, the company expects consolidated revenue to be in the range of $565 million to $575 million against previous guidance range of $555 million to $565 million. Net loss to be in the range of $107 million to $100 million against previous guidance range of $116 million to $108 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.91 USD | +0.74% | -4.61% | -7.85% |
May. 02 | North American Morning Briefing : Stock Futures -3- | DJ |
Apr. 30 | Needham Lowers Price Target on NeoGenomics to $19 From $24 Due to Peer Multiple Compression, Maintains Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-7.85% | 1.9B | |
-22.04% | 8.54B | |
+68.22% | 4.32B | |
-1.35% | 2.53B | |
-9.63% | 2.46B | |
-38.23% | 2.48B | |
-17.74% | 1.59B | |
-39.48% | 1.23B | |
+9.68% | 1.13B | |
+16.30% | 994M |
- Stock Market
- Equities
- NEO Stock
- News NeoGenomics, Inc.
- NeoGenomics, Inc. Revises Earnings Guidance for the Fiscal Year 2023